SCOPE FLUIDICS SA ZY-10 (S84) - Total Assets
Based on the latest financial reports, SCOPE FLUIDICS SA ZY-10 (S84) holds total assets worth €195.94 Million EUR (≈ $229.07 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See S84 total equity for net asset value and shareholders' equity analysis.
SCOPE FLUIDICS SA ZY-10 - Total Assets Trend (2021–2025)
This chart illustrates how SCOPE FLUIDICS SA ZY-10's total assets have evolved over time, based on quarterly financial data.
SCOPE FLUIDICS SA ZY-10 - Asset Composition Analysis
Current Asset Composition (December 2025)
SCOPE FLUIDICS SA ZY-10's total assets of €195.94 Million consist of 85.1% current assets and 14.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 47.5% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €5.93 Million | 3.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €17.97 Million | 9.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how SCOPE FLUIDICS SA ZY-10's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of SCOPE FLUIDICS SA ZY-10.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SCOPE FLUIDICS SA ZY-10's current assets represent 85.1% of total assets in 2025, a decrease from 86.7% in 2021.
- Cash Position: Cash and equivalents constituted 47.5% of total assets in 2025, up from 34.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, unchanged from 9.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 9.2% of total assets.
SCOPE FLUIDICS SA ZY-10 Competitors by Total Assets
Key competitors of SCOPE FLUIDICS SA ZY-10 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cowealth Medical China Co.Ltd.
SHG:603122
|
China | CN¥1.41 Billion |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
|
China | CN¥2.35 Billion |
|
Ningbo MedicalSystem Biotechnology Co Ltd
SHE:300439
|
China | CN¥3.66 Billion |
|
Bionet
TWO:1784
|
Taiwan | NT$3.08 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩131.23 Billion |
|
Check-Cap Ltd
F:7CC
|
Germany | €7.49 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
SCOPE FLUIDICS SA ZY-10 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.06 | 13.77 | 11.26 |
| Quick Ratio | 12.60 | 13.63 | 11.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €153.91 Million | €145.09 Million | €61.14 Million |
SCOPE FLUIDICS SA ZY-10 - Advanced Valuation Insights
This section examines the relationship between SCOPE FLUIDICS SA ZY-10's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.14 |
| Latest Market Cap to Assets Ratio | 0.45 |
| Asset Growth Rate (YoY) | 13.3% |
| Total Assets | €195.94 Million |
| Market Capitalization | $88.16 Million USD |
Valuation Analysis
Below Book Valuation: The market values SCOPE FLUIDICS SA ZY-10's assets below their book value (0.45x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: SCOPE FLUIDICS SA ZY-10's assets grew by 13.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SCOPE FLUIDICS SA ZY-10 (2021–2025)
The table below shows the annual total assets of SCOPE FLUIDICS SA ZY-10 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €195.94 Million ≈ $229.07 Million |
+13.34% |
| 2024-12-31 | €172.87 Million ≈ $202.10 Million |
+70.33% |
| 2023-12-31 | €101.49 Million ≈ $118.65 Million |
-70.68% |
| 2022-12-31 | €346.15 Million ≈ $404.69 Million |
+556.43% |
| 2021-12-31 | €52.73 Million ≈ $61.65 Million |
-- |
About SCOPE FLUIDICS SA ZY-10
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.